Lund, Camilla http://orcid.org/0000-0001-5162-7311
Ranea-Robles, Pablo http://orcid.org/0000-0001-6478-3815
Falk, Sarah http://orcid.org/0000-0003-3245-1845
Rausch, Dylan M. http://orcid.org/0000-0001-6095-4891
Skovbjerg, Grethe
Vibe-Petersen, Victoria Kamma
Krauth, Nathalie http://orcid.org/0000-0001-8048-7119
Skytte, Jacob Lercke http://orcid.org/0000-0003-0313-2124
Vana, Vasiliki
Roostalu, Urmas http://orcid.org/0000-0002-7849-2055
Pers, Tune H. http://orcid.org/0000-0003-0207-4831
Lund, Jens http://orcid.org/0000-0003-2338-6033
Clemmensen, Christoffer http://orcid.org/0000-0003-2456-9667
Funding for this research was provided by:
Lundbeckfonden (R238-2016-2859)
Novo Nordisk Fonden (NNF17OC0026114)
Article History
Received: 2 May 2023
Accepted: 18 January 2024
First Online: 8 February 2024
Competing interests
: C.C. is a co-founder of Ousia Pharma ApS, a biotech company developing therapeutics for the treatment of metabolic disease. The remaining authors declare no competing interests.